Genetic Mapping of a New Lafora Progressive Myoclonus Epilepsy Locus (EPM2B) on 6p22

Overview

Journal J Med Genet

Specialty Genetics

Date 2003 Sep 10

PMID 12960212

Citations 30

Authors

E M Chan

D E Bulman

A D Paterson

J Turnbull

E Andermann

F Andermann

G A Rouleau

A V Delgado-Escueta

S W Scherer

B A Minassian

Affiliations

Soon will be listed here.

Abstract

Background: Lafora disease is a progressive myoclonus epilepsy with polyglucosan accumulations and a peculiar neurodegeneration with generalised organellar disintegration. It causes severe seizures, leading to dementia and eventually death in early adulthood.

Methods: One Lafora disease gene, EPM2A, has been identified on chromosome 6q24. Locus heterogeneity led us to search for a second gene using a genome wide linkage scan in French-Canadian families.

Results: We mapped a second Lafora disease locus, EPM2B, to a 2.2 Mb region at 6p22, a region known to code for several proteins, including kinesins. Kinesins are microtubule dependent motor proteins that are involved in transporting cellular components. In neurones, they play a major role in axonal and dendritic transport.

Conclusion: Analysis of the present locus in other non-EPM2A families will reveal whether there is further locus heterogeneity. Identification of the disease gene will be of major importance towards our understanding of the pathogenesis of Lafora disease.

Citing Articles

A Novel Mutation in Lafora Disease and Update on Pathophysiology and Future Treatments.

Nordli D, Rao C, Delgado-Escueta A, Galan F Child Neurol Open. 2022; 9:2329048X221126361.

PMID: 36211619 PMC: 9537485. DOI: 10.1177/2329048X221126361.

Lafora Disease and Alpha-Synucleinopathy in Two Adult Free-Ranging Moose () Presenting with Signs of Blindness and Circling.

Ravi M, Lacson A, Pybus M, Ball M Animals (Basel). 2022; 12(13).

PMID: 35804532 PMC: 9264765. DOI: 10.3390/ani12131633.

Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.

Nitschke S, Sullivan M, Mitra S, Marchioni C, Lee J, Smith B Brain. 2022; 145(7):2361-2377.

PMID: 35084461 PMC: 9612801. DOI: 10.1093/brain/awac017.

Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis.

Pondrelli F, Muccioli L, Licchetta L, Mostacci B, Zenesini C, Tinuper P Orphanet J Rare Dis. 2021; 16(1):362.

PMID: 34399803 PMC: 8365996. DOI: 10.1186/s13023-021-01989-w.

Italian cohort of Lafora disease: Clinical features, disease evolution, and genotype-phenotype correlations.

Riva A, Orsini A, Scala M, Taramasso V, Canafoglia L, dOrsi G J Neurol Sci. 2021; 424:117409.

PMID: 33773408 PMC: 8166462. DOI: 10.1016/j.jns.2021.117409.

References

Krynetski E, Schuetz J, Galpin A, Pui C, Relling M, Evans W . A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A. 1995; 92(4):949-53. PMC: 42614. DOI: 10.1073/pnas.92.4.949. View

Schaffer A, Gupta S, Shriram K, Cottingham Jr R . Avoiding recomputation in linkage analysis. Hum Hered. 1994; 44(4):225-37. DOI: 10.1159/000154222. View

Fu G, Grosveld G, Markovitz D . DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. Proc Natl Acad Sci U S A. 1997; 94(5):1811-5. PMC: 19999. DOI: 10.1073/pnas.94.5.1811. View

Kruglyak L, Lander E . Faster multipoint linkage analysis using Fourier transforms. J Comput Biol. 1998; 5(1):1-7. DOI: 10.1089/cmb.1998.5.1. View

Broman K, Murray J, Sheffield V, White R, Weber J . Comprehensive human genetic maps: individual and sex-specific variation in recombination. Am J Hum Genet. 1998; 63(3):861-9. PMC: 1377399. DOI: 10.1086/302011. View

Minassian B, Lee J, Herbrick J, Huizenga J, Soder S, Mungall A . Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet. 1998; 20(2):171-4. DOI: 10.1038/2470. View

Minassian B, Sainz J, Serratosa J, Gee M, Sakamoto L, Bohlega S . Genetic locus heterogeneity in Lafora's progressive myoclonus epilepsy. Ann Neurol. 1999; 45(2):262-5. DOI: 10.1002/1531-8249(199902)45:2<262::aid-ana20>3.0.co;2-9. View

CAVANAGH J . Corpora-amylacea and the family of polyglucosan diseases. Brain Res Brain Res Rev. 1999; 29(2-3):265-95. DOI: 10.1016/s0165-0173(99)00003-x. View

Goldstein L, Yang Z . Microtubule-based transport systems in neurons: the roles of kinesins and dyneins. Annu Rev Neurosci. 2000; 23:39-71. DOI: 10.1146/annurev.neuro.23.1.39. View

10.

Minassian B, Ianzano L, Meloche M, Andermann E, Rouleau G, Delgado-Escueta A . Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology. 2000; 55(3):341-6. DOI: 10.1212/wnl.55.3.341. View

11.

Ganesh S, Agarwala K, Ueda K, Akagi T, Shoda K, Usui T . Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum Mol Genet. 2000; 9(15):2251-61. DOI: 10.1093/oxfordjournals.hmg.a018916. View

12.

Minassian B, Andrade D, Ianzano L, Young E, Chan E, Ackerley C . Laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase. Ann Neurol. 2001; 49(2):271-5. View

13.

Jamain S, Quach H, Fellous M, Bourgeron T . Identification of the human KIF13A gene homologous to Drosophila kinesin-73 and candidate for schizophrenia. Genomics. 2001; 74(1):36-44. DOI: 10.1006/geno.2001.6535. View

14.

Wang J, Stuckey J, Wishart M, Dixon J . A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. J Biol Chem. 2001; 277(4):2377-80. DOI: 10.1074/jbc.C100686200. View

15.

Minassian B . Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease. Adv Neurol. 2002; 89:199-210. View

16.

Ganesh S, Delgado-Escueta A, Sakamoto T, Avila M, Machado-Salas J, Hoshii Y . Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet. 2002; 11(11):1251-62. DOI: 10.1093/hmg/11.11.1251. View

17.

Ianzano L, Zhao X, Minassian B, Scherer S . Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product. Genomics. 2003; 81(6):579-87. DOI: 10.1016/s0888-7543(03)00094-6. View

18.

Collins G, COWDEN R, Nevis A . Myoclonus epilepsy with Lafora bodies. An ultrastruc- tural and cytochemical study. Arch Pathol. 1968; 86(3):239-54. View

19.

Sakai M, Austin J, Witmer F, Trueb L . Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology. 1970; 20(2):160-76. DOI: 10.1212/wnl.20.2.160. View

20.

Lathrop G, Lalouel J, Julier C, Ott J . Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci U S A. 1984; 81(11):3443-6. PMC: 345524. DOI: 10.1073/pnas.81.11.3443. View